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Abstract 
 
Objectives 
To determine the potential costs and health benefits of a serum-based spectroscopic triage 
tool for brain tumours, that could be developed to reduce diagnostic delays in the current 
clinical pathway. 
Design 
A model-based health pre-trial economic assessment. Decision tree models were constructed 
based on simplified diagnostic pathways. Models were populated with parameters identified 
from rapid reviews of the literature and clinical expert opinion. 
Setting 
Explored as a test in both primary and secondary care (neuroimaging) in the UK health 
service, as well as application to the US.  
Participants 
Calculations based upon an initial cohort of 10,000 patients. In primary care, it is estimated 
that the volume of tests would approach 75,000 per annum. The volume of tests in secondary 
care is estimated at 53,000 per annum.  
Main Outcome Measures 
The primary outcome measure was quality adjusted life years (QALYs), which were 
employed to derive incremental cost-effectiveness ratios (ICERs) in a cost-effectiveness 
analysis.  
Results 
Results indicate that using a blood-based spectroscopic test in both scenarios has the potential 
to be highly cost-effective in a health technology assessment (HTA) agency decision making 
process, as ICERs were well below standard threshold values of £20,000 to £30,000 per 
QALY. This test may be cost-effective in both scenarios with test sensitivities and 
specificities as low as 80%; however, the price of the test would need to be lower (less than 
approximately £40). 
Conclusion 
Use of this test as triage tool in primary care has the potential to be both more effective and 
cost saving for the health service. In secondary care, this test would also be deemed more 
effective than the current diagnostic pathway.
Strengths and Limitations of this Study 
x Simplified models of clinical pathways were mapped with input from, and consensus among, a 
wide range of clinical experts including neurosurgeons, neurooncologists, neuropathologists, 
neuroradiologists, and primary care experts. 
x The spectroscopic blood test was highly sensitive and specific in retrospective data, with 
performances of 91.5 and 83.0% respectively. There is potential for this to contribute towards 
improved prognosis for patients, as well as healthcare savings. 
x This study is based upon proof-of-concept studies, in advance of a pending prospective clinical 
trial. As these samples are retrospective, there is the possibility the diagnostic performance will 
not be as high in prospective studies. 
x A lack of clinical trial evidence necessitates the estimate of long-term benefits of improved 
diagnostic protocols based on disease natural history models. This creates additional 
uncertainties. 
x The precise patient population for whom the test may be suitable in the primary care setting is 
difficult to establish at this stage in development. This study considers a limited definition of 
eligibility that may need revision in light of future evidence.    
 
Introduction 
At an average of 20 years, patients with malignant brain tumours have the highest number of 
years of life lost, compared to all other primary cancers.1 This, at least in part, may relate to 
diagnostic delays, reflecting the non-specific early symptoms, such as headache and 
dizziness, from which general practitioners (GPs) must identify patients at risk for further 
investigation. The lack of a low-cost diagnostic and/or screening tools available within the 
health service contributes to this delay. We have recently demonstrated that a spectroscopic 
test using blood-serum is able to effectively identify brain tumours in patients with 
sensitivities and specificities as high as 91·5% and 83% respectively, in a tissue bank case-
control series.2,3  This approach is based upon Fourier-transform infrared (FTIR) 
spectroscopy and can detect disease-specific signatures, which are extracted mathematically 
using pattern recognition and machine learning algorithms.  
Current Diagnostic Pathway 
Currently, patients who are symptomatic with a brain tumour visit their GP on average five 
times before being referred to secondary care.4 Partly as a result of this diagnostic delay up to 
61% of brain tumour diagnoses occur in an emergency setting, often following a seizure.5 
Patients diagnosed by the emergency route have a poorer prognosis.6,7 For some patients this 
may be because the disease is at a more advanced stage at diagnosis. The complications 
precipitating the emergency admission make an additional contribution to mortality. 
Screening programmes for breast, prostate, cervical, and colorectal cancer have proved 
effective for diagnosing patients at an earlier stage, which can result in a better prognosis.8-11 
These screening programmes have had a significant impact in reducing the number of 
patients presenting as an emergency. To date there has been no accessible and economically 
viable diagnostic tool for early detection of asymptomatic and symptomatic brain tumours.12 
The addition of a rapid and accurate blood test for patients with suspected primary brain 
tumours (symptomatic patients) therefore has the potential to improve outcomes by allowing 
prioritisation of patients most at risk of a brain tumour for further investigation. Under the 
current patient pathway it is not feasible to provide fast-track diagnostic imaging because the 
number of patients with non-specific headache symptoms is very large and the positive 
predictive value (PPV) on the basis of symptoms alone is less than 3% for all symptoms other 
than a new-onset seizure.13,14 
Magnetic resonance imaging (MRI) and computed tomography (CT) are the current gold 
standard for identifying structural brain lesions including tumours. Treatment decisions made 
at the neuro-oncology multidisciplinary team (MDT) meeting are often based on the imaging 
alone. Following surgical resection or biopsy with histopathology and molecular analysis, 
definitive treatment can be planned.15 Surgery to secure the tissue diagnosis has a small risk 
to the patient of neurological deterioration and death.16  
The diagnostic pathway also represents a significant cost burden to the health service, with a 
single MRI and CT scan in the UK costing around £164 and £85, respectively (National 
Schedule of Reference Costs [2014-15], Medicare Physician Fee Schedule 2016). A typical 
timeframe of the diagnostic pathway for brain tumours, specifically primary gliomas, is 
illustrated in Figure 1, and effectively highlights the significant wait that a symptomatic 
patient may have before receiving brain imaging. Even from this stage, regardless of the time 
to GP referral or emergency presentation, full diagnosis may take a further 5 weeks.   
Serum Spectroscopic Diagnostics 
This novel blood test for early brain tumour detection is based upon the interaction of 
infrared (IR) light with biological components of blood serum (Figure 2). Specifically, using 
attenuated total reflectance (ATR)-FTIR spectroscopy, specific bond vibrations of given 
molecules can be elucidated from serum samples, thus providing a unique insight into the 
composition via an absorbance spectrum.17 Benefits of an ATR-FTIR based approach include 
a robust, user-friendly methodology without extensive sample preparation, that would readily 
fit into a clinical setting.18 In short, serum is obtained according to standard protocols and can 
be snap frozen and stored at -80° until the point of analysis. A small volume of serum is 
required for analysis (1-5 µL), which is pipetted onto a crystal, known as an internal 
reflection element (IRE), where IR non-destructively interacts with the sample and produces 
an IR spectrum, with peaks representative of known bond vibrations and hence biomolecular 
constituents. 
Blood serum is a complex medium that contains a variety of biomolecules, including around 
20,000 proteins, that may be employed as diagnostic biomarkers.19 In the case of brain 
tumours, such blood based technologies are limited, due to a lack of an established brain 
tumour specific diagnostic biomarker.20 With our spectroscopic approach, rather than derive 
single biomarker specific information, a global signature is obtained, which encompasses the 
entire biomolecular makeup. This is epitomised as an equally complex biological absorbance 
spectrum, which contains a wealth of diagnostic information (an example may be seen in 
Figure 3).  
Pattern recognition and machine learning algorithms using spectral features from FTIR data 
have been demonstrated as rapid and accurate for separating primary brain cancer and non-
cancer cases.2,21  When these algorithms are applied to this information rich dataset, the 
relationship between all biological components of the sample is ascertained, providing a 
multi-dimensional analysis of the sample. 
In the case-control setting, this approach has been able to not only detect between cancer and 
non-cancer, but also stratify based upon cancer pathology.2 For further information and in-
depth description of the methodology, we direct the readers to the following fundamental 
review and recent research papers.2,3,17,21 The ability to triage patients likely to have a brain 
tumour based on serum sample alone raises the possibility of systematic triaging prior to 
investigation with more expensive (MRI/CT imaging) and invasive (biopsy) tests. One major 
impact of having a serum test available would be a possible reduction in the number of 
unnecessary brain scans; however, as this test is also able to differentiate between primary 
and secondary tumours, there could also be a knock-on reduction of chest and abdomen scans 
which are conducted to rule out primary disease elsewhere. There is also the possibility that 
this approach will reduce the incidence of incidental abnormalities which in themselves can 
cause considerable distress.  Ultimately, it is expected that this could allow earlier and 
potentially more effective treatment of brain tumours.   
It is important to note that this study is based upon proof-of-concept studies, in advance of a 
pending clinical trial. As these samples are retrospective, there is the possibility the 
diagnostic performance will not be as high in prospective studies. Additional to determining 
the true diagnostic accuracy of the technique, the planned clinical trial held in primary care 
will also reveal the suitable patient population for the test, as well as the long-term benefits of 
an improved diagnostic pathway. 
Aims & Objectives 
The aim of the economic evaluation is to assess the potential cost-effectiveness of this 
spectroscopic technology, in advance of any prospective study results being available. There 
are three main objectives for the evaluation. The first objective is to create a map of where 
the test could be used in the clinical pathway. The second is to assess the potential cost-
effectiveness of the technology, if the performance shown in the case-control study is 
replicated prospectively. This will give an indication of whether the technology would meet 
the criteria for acceptance for use in the National Health Service that are applied by Health 
Technology Assessment agencies (HTA). Related to this, the third objective is to define the 
level of performance in prospective trials, and any additional evidence that would be needed 
to meet the cost-effectiveness criteria of an HTA decision-making process. This can include 
diagnostic performance and also effects on long-term outcomes such as survival and resource 
use. To achieve these objectives a simplified economic model of two important clinical 
scenarios is used to explore cost effectiveness. 
 
 
 
Methodology 
 
Mapping the Clinical Pathway 
In order to appreciate the current clinical pathway and determine an appropriate entry point 
for a serum spectroscopic test, a pan-UK clinical focus group was established. This cohort 
included neurosurgeons, clinical and medical oncologists, neuropathologists, 
neuroradiologists, academic GPs with special interests, and experts in primary care 
diagnostics (see Appendix 1). 
Cost Effectiveness Analysis 
A cost-effectiveness analysis (CEA) was conducted to calculate the effects on health 
outcomes and health service costs of introducing spectroscopic testing in each of two 
scenarios. The health outcomes considered were life-years and quality-adjusted life-years 
(QALYs).  
A decision tree was used to model the pathway for patients presenting with symptoms 
warranting a referral for MRI/CT imaging for suspected brain tumour (Figure 4). Separate 
models were considered for primary and secondary care. The time horizon of the model is 2 
years and the perspective is that of the health care service. A two-year horizon was selected 
because of the short duration of survival in this patient group: median survival is 
approximately 1 year for high grade gliomas, which are the commonest malignant primary 
brain tumour. In all scenarios the comparator is the current diagnostic pathway (i.e. imaging 
alone). Further details regarding the node probabilities, simplifications and assumptions of 
the model can be found in Appendix 2. 
Diagnostic Performance  
The sensitivity and specificity of the test for detecting brain tumours has been demonstrated 
in a series of case-control studies using historical samples from the Brain Tumour North West 
and Walton Centre NHS bio-banks.2,3 In the key case-control study nine FTIR spectra were 
collected from each of 433 patients.3 Of these 134 were from patients with primary brain 
tumours (64 high grade glioma), 177 were from patients with cerebral metastases and 122 
were from non-cancer controls. FTIR spectra were analysed using the random forest method 
to fit a classification model. Classification performance was estimated by applying the fitted 
model to a test set containing 20% of the patients from the original data set that were not used 
in the model fitting step (hold-out test set). Classification statistics are computed as averages 
of this process, iterated 96 times using random training and test sets. Under the best available 
model, sensitivity estimated by this method was 92·8% and specificity was 91·5% for the 
analysis of cancerous vs. non-cancerous serum.3 These classification statistics were 
established using 96 independent iterations of a Random Forest model, and resulted in 
standard deviations of 1.1% and 1.9% respectively. 
Establishing whether the performance demonstrated case-control data from historical samples 
translates to equivalent performance when applied prospectively in clinical practice is the 
subject of a planned clinical trial. This is critical to demonstrating the clinical and cost-
effectiveness of a serum spectroscopy test as part of the diagnostic pathway for brain 
tumours. 
Prevalence of disease 
Prevalence data were sourced from the literature based on clinical expert guidance. Brain 
tumour prevalence in scenario 2 (secondary care) was assumed to be 3% based on observed 
rates of primary brain tumour diagnosis among patients referred for brain imaging for 
suspected cancer in secondary care.22-24 In scenario 1 (primary care) an estimated prevalence 
of 0·5% is used based on case-control evidence and expert opinion of the prevalence among 
patients who would be considered for direct access imaging, using MRI or CT, where this is 
available and referral to neurology where it is not.25,26 An alternative prevalence of 1% was 
explored for scenario 1 based on unpublished data from a direct access imaging service in the 
UK (P. Brennan, personal communication). 
The effect of serum spectroscopy testing on the time-to-diagnosis and time-to-treatment is 
discussed in Appendix 3, additional to the effect of testing on the use of imaging studies, and 
also on the patient outcomes. The primary assumptions in this model are that first, the 
expected time-to-diagnosis would match the current median time-to-diagnosis for patients 
presenting with brain tumour in emergency care as observed in Aggarwal et al.5 Furthermore, 
based upon expert opinion, it is assumed that in secondary care all patients would continue to 
imaging, while in primary care 50% would continue to imaging following a negative 
spectroscopy result. This is a conservative estimate associated with the possibility that an 
imaging test will still be required in some cases based on interpretation of a patient¶s 
symptoms and the other non-tumour diagnoses being considered by the clinician.  Finally, the 
effects of early diagnosis on the outcome of brain tumours is estimated using literature 
describing fitting natural history models to observational datasets of high grade glioma 
patients.27,28 
Utility Weights 
Health state utility weights are applied to life-years to generate quality adjusted life years 
(QALYs). A systematic review of health state utility weights for high grade glioma, the most 
common and aggressive primary brain tumour, was conducted to identify suitable utility 
weights. Due to heterogeneity it was not considered suitable to pool the estimates. The most 
appropriate health state utility weight was taken from a previous UK economic evaluation of 
glioblastoma treatment.29 A value of 0·89 was used in the base case. 
Resource Use and Costs 
Resource use includes the application of a spectroscopic serum test to all patients prior to 
imaging, the imaging studies used in the diagnostic process, outpatient neurology clinic visits 
and general practitioner visits. In the UK analysis, unit costs for imaging studies are taken 
from UK NHS reference costs (2014/15), clinic and GP visits from the PSSRU costs schedule 
(Table 1). In the USA analysis, unit costs are taken from Medicare reimbursement schedules. 
Unit costs of the test were applied at an upper bound and lower bound rather than a single 
value as these products have not yet been commercialized. Bounds were set by consultation 
with scientists developing the tests. Additional resource use and cost assumptions are 
described in Appendix 3.  
Table 1. Unit costs and comparison for the brain tumour diagnostic pathway 
Item UK Cost per unit (£) 
(2015 prices) 
USA cost per 
unit ($) (2016 
prices) 
Source(s) 
CT imaging study 
[CT head] 
85 163 National Schedule 
of Reference Costs 
(2014 ± 15),  
Medicare Physician 
Fee Schedule 2016 
 
MRI imaging study 
[MRI brain with 
contrast] 
164 380 National Schedule 
of Reference Costs 
(2014 ± 15),  
Medicare Physician 
Fee Schedule 2016 
 
Neurology outpatient 
appointment 
35 76 PSSRU 2016, 
Medicare Physician 
Fee Schedule 2016 
 
GP visit 47·25 76 PSSRU 2016, 
Medicare Physician 
Fee Schedule 2016 
 
Stable disease 
monitoring costs 
116 per 3 months 154 29, exchange rate 
adjusted 
 
Serum spectroscopy 
test 
Lower limit: 50 
Upper limit: 100 
Lower limit: 100 
Upper limit: 200  
Assumed prices 
 
Incremental cost effectiveness ratios (ICER) 
The comparative cost-effectiveness of spectroscopic testing compared to no testing is 
summarized by the ICER defined as: ܫܥܧܴ ൌ ܥ௦ െ ܥ௡ܪ௦ െ ܪ௡ ܥ௦ and ܥ௡ are the total costs with spectroscopic testing and no testing respectively.  
Equivalently ܪ௦ and ܪ௡ are the total QALYs with and without spectroscopic testing. The 
ICER can be interpreted as the additional cost per QALY gained. 
Base Case and Sensitivity Analysis 
ICERs were calculated for scenarios 1 and 2 using the base case parameter estimates. Base 
case analysis was repeated for UK and USA settings. Additional sensitivity analyses are 
reported for the UK setting only. 
Sensitivity analyses included one-way sensitivity analysis (OWSA), systematically varying a 
single parameter in the model, and scenario analysis in which specific model assumptions 
were altered. OWSA were conducted for test sensitivity, specificity and test cost. Scenario 
analyses included assuming an additional consultation cost for discussion of test results, 
assuming a higher proportion of patients continue to imaging following a negative 
spectroscopy result in primary care, and using mean survival rather than median survival. 
A probabilistic sensitivity analysis (PSA) was conducted to explore the effects of joint 
uncertainty in the parameter estimates on the model results.30  
Patient and Public Involvement 
Patients and the public were not actively involved in the formation of this study. The impact 
of the test on clinical decision making was the priority in this instance; however, the 
involvement of patients going forward will be fundamental to understanding the tests uptake 
into the health services.  
Results 
 
Mapping the clinical pathway 
For the first study objective, initial discussion with clinical experts indicated that there are 
potential uses for the test in both primary and secondary care. The main advantage of 
employing a cost-effective spectroscopic blood test in the diagnostic pathway is to use it as a 
triage test. This prioritises more urgent cases for access to services, and acts as a gate-keeper 
(requiring a positive result in some conditions to give access to services) for imaging studies. 
Two clinical scenarios are mapped out below and subsequently explored in this early 
economic evaluation of the serum spectroscopy test for aiding diagnosis of brain tumours: 
1. Triage tool in primary care 
The primary care scenario explores a population of patients with a clinical 
presentation that warrants further investigation of possible brain tumour. This would 
include some patients with headaches and some with focal neurological deficits. This 
is the group of patients who would be considered for direct access imaging, using 
MRI or CT, where this is available and referral to neurology where it is not.31 The 
blood test is used to provide rapid information, within 24 hours, where a positive 
result would lead to patients receiving more timely access to imaging. It may also be 
the case that negative test results, in addition to establishing the low probability of a 
brain tumour, could also provide some reassurance for those patients that must wait 
for imaging. The total volume of tests would be approximately 75,000 per year in the 
UK (see Appendix 4 for further details). 
2. Triage tool in secondary care 
In this scenario the population is the group of patients that are currently referred for 
imaging studies from secondary care for suspected brain tumour, typically via 
neurology clinics. This is the patient group for whom the clinical presentation has the 
highest positive predictive value (PPV). However, even in this high risk group, the 
odds of a brain tumour being present are approximately 1:33.22-24 Again, the 
spectroscopy test is used to provide rapid information to allow a subset of these 
patients to access immediate imaging and provide reassurance to other patients who 
may have to wait longer for definitive imaging studies and diagnosis. The extent of 
the benefits of triage in this scenario is likely to vary by locality depending on the 
capacity constraints on imaging and pathology services. This evaluation uses 
estimates of the delays in diagnosis, and potential improvements in the speed of 
diagnosis, from a consecutive patient case series in London, UK.5 The total volume of 
tests if this scenario occurred would be approximately 53,000 per year in the UK (see 
Appendix 4 for further details). 
 
Cost Effectiveness Assessment 
 
The standard threshold value per QALY gained in the UK, is considered to be between 
£20,000 to £30,000. Below this value, a healthcare intervention may be considered cost 
effective, whereas a negative ICER value would be deemed cost saving. Base case results for 
primary care (scenario 1) and secondary care (scenario 2) are presented in Table 2. Note 
results are reported for cohorts of 10,000 patients. 
 
 
Table 2. Incremental QALYs, costs and ICERs for Scenarios 1 and 2, UK and USA 
 Scenario 1 ± Primary Care  Scenario 2 ± Secondary Care 
Serum 
spectroscopy 
test cost (£) 
¨QALY ¨Cost ICER  ¨QALY ¨Cost ICER 
UK 
50 8·81 -422,116 -47,913 
(dominates) 
 52·86 527,646 9,982 
100 8·81 77,884 8,840  52·86 1,027,646 19,441 
USA 
100 8·81 -1,718,475 -195,058 
(dominates) 
 52·86 536,702 10,153 
200 8·81 -218,475 -24,798 
(dominates) 
 52·86 2,036,702 38,530 
¨4$/<¨&RVWGLIIHUHQFHLV4$/<V&RVWVZLWKVHUXPVSHFWURVFRS\WHVW± without test), 10K patients 
ICER: Incremental cost-effectiveness ratio 
 
Incremental cost-effectiveness ratios were well below standard threshold values of £20,000 to 
£30,000 per quality adjusted life year (QALY) gained used in the UK, and similar thresholds 
used internationally, provided the test cost did not exceed £100. The base case results 
demonstrate that the serum spectroscopy test dominates (more effective and less costly) 
standard care at the lower bound of test cost in the primary care setting in both the UK and 
USA. At the upper bound of test cost the ICERs may be within commonly used thresholds or, 
in the case of the USA, remain dominant to standard care. In the secondary care setting 
ICERs of £9,982 and $10,153 at the lower bounds of test cost indicate that this test is 
potentially cost-effective in this setting. At the upper bounds ICERs may still be within 
commonly used thresholds for cost-effectiveness.  
 
Sensitivity Analysis Results 
The performance of the test with regards to levels of sensitivity and specificity are addressed 
using sensitivity analysis. OWSA results for a range of test specificities are displayed in 
Figure 5 and 6, for primary and secondary care respectively, displaying the ICER with 
varying test specificity. Note that the estimated QALYs do not change with specificity in the 
model therefore changes in the ICER are due solely to changes in incremental costs. Varying 
sensitivity changes both estimated QALYs and estimated costs therefore results of the OWSA 
for test sensitivity are presented on the cost-effectiveness plane (Appendix 5). In primary 
care, using the upper cost limit of £100 it is evident that the test is deemed cost effective at 
specificities of around 0·9 and above, where the ICER is below standard thresholds. In 
contrast, at the lower cost limit, the test is cost effective at specificities above 0·8. Although 
the serum spectroscopy test is not cost saving at low cost (or near perfect specificities), the 
test is still considered cost effective at specificity levels around 0·7 and 0·8 for £50 and £100 
pricing respectively. 
The OWSA results highlight how ICERs in scenario 2 (secondary care) are strongly 
influenced by test sensitivity while ICERs in scenario 1 (primary care) are more strongly 
influenced by test specificity. These features are a result of the varying prevalence of disease 
and the assumption in scenario 2 that 100% of patients are referred for imaging following 
negative result. It should be noted that test specificity is important in both scenarios. 
Relatively small improvements in test specificity can substantially change the ICER, while 
larger improvements in test sensitivity are required to substantially alter the ICERs. 
Additional scenario analyses are also reported in Appendix 5. These demonstrate that results 
are robust to using mean survival estimates rather than median survival estimates and 
including additional consultation costs for positive test results. If the prevalence of brain 
tumours in Scenario 1 is 1% rather than 0·5% the incremental QALYs increase substantially 
and the ICERs are reduced. 
 
The PSA results reported in Figure 7 and 8 indicate that at a test cost of £50 and an ICER 
threshold of £30,000 per QALY there is a near 100% probability the serum spectroscopy test 
is cost-effective in scenario 1 and approximately 90% probability it is cost-effective in 
scenario 2. The corresponding probabilities at the upper bound cost of £100 are 
approximately 85% and 75%.    
Discussion 
 
This economic evaluation establishes the potential for serum spectroscopy to have a role in 
the diagnosis of both benign and malignant brain tumours in both primary and secondary 
care. The potential costs and health benefits of testing using a spectroscopic method prior to 
CT/MRI tests (or in some scenarios to avoid imaging) have been estimated based on a 
mathematical model with parameter values taken from published studies and expert opinion. 
This diagnostic tool is sensitive to all brain tumours (benign or malignant), however, this 
assessment is closely aligned with the diagnosis of primary gliomas, where there is a 
maximum potential benefit to the health service.  
The major limitations of this analysis relate to the use of proof-of-concept studies and a 
disease natural history model rather than direct clinical trial evidence. This creates additional 
uncertainties. Results should be interpreted as indicative and used primarily to guide future 
evidence generation. Furthermore, the scenarios explored were limited in scope; future 
studies should continue to refine understanding of the role of the test in real-world clinical 
decision making.  
 
When used as a triage tool in primary care, this novel test has the potential to deliver 
improvements in health outcomes and also to reduce costs. At the lower end of test costs, the 
technology would be cost-saving for the health service. At higher test costs the technology is 
still likely to be considered cost-effective in HTA agency decision processes. 
In Scenario 2, in which serum spectroscopy is used as a triage tool in secondary care, the 
technology will create additional costs but also produce sizable health benefits. At test costs 
of under £100 ($200) the technology would be likely to be considered as a cost-effective use 
of resources in HTA agency decision processes in the UK (and USA). It is assumed that in 
both scenarios, the uptake of the test in the USA would mirror that of the UK; however, this 
would need to be explored further, alongside clinical experts of the USA care pathways. 
Sensitivity analyses have demonstrated the importance of diagnostic performance on the cost-
effectiveness of the test. In particular, test specificity is important in the primary care setting. 
If test specificity is 87·5% or worse the technology may not be considered cost-effective at 
higher values of assumed test cost. This is due to the increased number of false positive 
results in this low prevalence population, generating a greatly increased proportion of fast-
track imaging studies which increases costs.  
To strengthen the case that this approach represents a cost-effective use of healthcare 
resources it is necessary to establish the diagnostic performance of the test prospectively. 
This can be accomplished by a suitably large cohort study in which serum spectroscopy is 
used alongside current clinical practice in one of the patient groups included in this 
evaluation. It would be appropriate to initially target the secondary care patient population, 
because the higher prevalence of disease in this group will reduce the sample size needed to 
accurately estimate diagnostic performance.  
Decision makers are often most interested in patient outcomes, such as survival, rather than 
intermediate outcomes, such as accuracy or speed of diagnosis (although this latter point is 
vital for treatment of high grade gliomas). From this perspective, a randomized trial, or a 
prospective cohort study with extended follow-up, may be required to fully establish the size 
of survival and quality-of-life benefits of including a serum spectroscopy test in the 
diagnostic pathway. A trial with primary outcomes relating to survival and quality-of-life 
would be specific to either the primary or secondary care setting (rather than generalisable to 
both), would need a large sample size, and would also require a follow-up period to capture 
survival benefits. In the case of malignant glioma this would require a period of at least 24 
months. Such a trial would clearly be expensive, time consuming and may be unfeasible. 
Decision makers may be willing to make a decision on implementation of the blood test 
based on the modeled effects of improvements in intermediate outcomes on later patient 
outcomes. In this situation, the model proposed in this evaluation, populated with diagnostic 
performance and other data from a prospective trial, could be used to inform decisions about 
the wider adoption of the technology.  
Future developments beyond trials such as emerging epidemiological evidence and new 
technologies should also be included in any future evaluations. It was not possible to foresee 
and include all such possible scenarios in this early evaluation but that should not preclude 
assessment in the light of new evidence. Updated analysis should inform any decisions about 
system wide implementation. 
Several results in this analysis suggest cost savings through reduced use of imaging for 
patients with a negative test result. To make the case that a serum spectroscopic test can 
improve the efficiency of the diagnostic pathway prospective studies will also need to explore 
the impact of these test results on clinician and patient imaging study decisions. The 
possibility remains that the test may triage patients, but may not reduce the number of scans 
being conducted, and could potentially increase the demand on imaging. For example, if the 
test is applied to a wider population than intended in primary care due to the availability of 
such a non-invasive test effectively lowering the threshold for investigation. This highlights 
the need to stud decision making in this area prior to any implementation in primary care. 
Nevertheless, this triaging of patients would still benefit each patient that is provided with an 
early diagnosis.    
This evaluation has explored the potential for serum spectroscopy to be a cost-effective 
addition to the diagnostic pathway for brain tumours. It has demonstrated that in specific 
scenarios this novel test may be an effective and cost-effective technology in reducing the 
delay to diagnosis for patients with brain tumours. Prospective trials are required to provide 
definitive evidence.  
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FIGURE LEGENDS 
 
Figure 1. The diagnostic pathway of brain tumours. Timings relate to the diagnosis of high 
grade gliomas and are based upon discussion with the Clinical Focus Team and Aggarwal et 
al. (2015)5. (OPD ± Outpatient department; MDT ± Multidisciplinary team)  
Figure 2. Attenuated total reflectance (ATR)-Fourier transform Infrared (FTIR) 
spectroscopic test of blood serum for the diagnosis and stratification of brain tumours using 
machine learning algorithms. 
 
Figure 3. An unprocessed spectrum derived from human blood serum using ATR-FTIR 
spectroscopy. Spectral regions correspond to known bond vibrations and can therefore be 
associated with groups of biomolecules such as protein, lipid, phosphate and carbohydrates. 
Broad examples of blood serum constituents are listed.  
Figure 4. A decision tree model describing the integration of a serum spectroscopy test in the 
current diagnostic pathway, and the effect on MRI/CT imaging for suspected brain tumour.  
Figure 5 ± Incremental cost effectiveness ratios (ICERs) at various specificities in primary 
FDUHµ6FHQDULR¶7KH,&(5WKUHVKROGLVGLVSOD\HGDVDGDVKHGKRUL]RQWDOOLQH 
Figure 6 - Incremental cost effectiveness ratios (ICERs) various specificities in Secondary 
&DUHµ6FHQDULR¶7KH,&(5WKUHVKROGLVGLVSOD\HGDVDGDVKHGKRUL]RQWDOOLQH 
Figure 7 ± Cost effectiveness acceptability curve (CEAC) at £50 and £100 per test ± Primary 
FDUHµ6FHQDULR¶ 
Figure 8 ± Cost effectiveness acceptability curve (CEAC) at £50 and £100 per test ± 
Secondary care ³6FHQDULR´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